Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Naruhiko Ikoma

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9825-9234; OpenAlex author ID A5078455132. Sources: OpenAlex.

Their work

Papers
36 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
104
Papers, trials and grants by year

2020: 4 papers · 2021: 6 papers · 2022: 6 papers · 2023: 7 papers · 2024: 3 papers · 2025: 2 papers · 2026: 8 papers

Papers 36

  1. Site-Specific Outcomes and Genomics in Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1093/oncolo/oyag423↗
  2. Presentation, Management, and Outcomes of Cyst-Associated Pancreatic Cancer Versus Classic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002608↗
  3. Clinical and Molecular Characteristics of Patients With Young-Onset and Average-Onset Pancreatic Adenocarcinoma. Co-author DOI 10.1200/po-25-00703↗
  4. Incidence of Venous Thromboembolism in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Chemotherapy. Co-author DOI 10.1245/s10434-025-18691-x↗
  5. ASO Visual Abstract: Incidence of Venous Thromboembolism in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Chemotherapy. Co-author DOI 10.1245/s10434-025-18865-7↗
  6. Evaluation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Localized Pancreatic Cancer: Trans-Atlantic Pancreatic Surgery Consorti… Last author DOI 10.1245/s10434-026-20620-5↗
  7. ASO Author Reflections: Can Progression-Free Survival Replace Overall Survival in Localized Pancreatic Cancer? First author DOI 10.1245/s10434-026-20716-y↗
  8. ASO Visual Abstract: Evaluation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Localized Pancreatic Cancer: Trans-Atlantic Pancre… Last author DOI 10.1245/s10434-026-20742-w↗
  9. Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer. Last author DOI 10.1097/sla.0000000000006269↗
  10. KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-025-01696-0↗
  11. Escalated-dose radiotherapy for unresected locally advanced pancreatic cancer: Patterns of care and survival in the United States. Co-author DOI 10.1002/cam4.7434↗
  12. Effect of surgical approach on early return to intended oncologic therapy after resection for pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00464-024-11022-3↗
  13. The Association between Sampling and Survival in Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Co-author DOI 10.3390/cancers16193312↗
  14. Quality of superior mesenteric and hepatic artery dissection in robotic pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1002/jhbp.1218↗
  15. Incidence of Postoperative Complications Following Pancreatectomy for Pancreatic Cystic Lesions or Pancreatic Cancer. Co-author DOI 10.1007/s11605-022-05534-3↗
  16. Integrated Pathologic Score Effectively Stratifies Patients With Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant Therapy and Pancreaticoduodenectomy. Co-author DOI 10.1097/pas.0000000000002013↗
  17. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000005184↗
  18. Effects of a Pragmatic Home-based Exercise Program Concurrent With Neoadjuvant Therapy on Physical Function of Patients With Pancreatic Cancer: The PancFit Ran… Co-author DOI 10.1097/sla.0000000000005878↗
  19. Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy. Co-author DOI 10.3390/cancers15092608↗
  20. Comparative Analyses of the Clinicopathologic Features of Short-Term and Long-Term Survivors of Patients with Pancreatic Ductal Adenocarcinoma Who Received Neo… Co-author DOI 10.3390/cancers15123231↗
  21. Prognostic significance of preoperative and postoperative CA 19-9 normalization in pancreatic adenocarcinoma treated with neoadjuvant therapy or surgery first. Co-author DOI 10.1002/jso.26989↗
  22. NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. Co-author DOI 10.1016/j.ctro.2021.12.012↗
  23. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreati… Co-author DOI 10.1016/j.ijrobp.2022.06.089↗
  24. AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatment sequencing. Co-author DOI 10.1016/j.suronc.2021.101673↗
  25. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci151604↗
  26. Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer. Co-author DOI 10.6004/jnccn.2022.7018↗
  27. History of preoperative therapy for pancreatic cancer and the MD Anderson experience. Co-author DOI 10.1002/jso.26394↗
  28. Perioperative blood transfusions and survival in resected pancreatic adenocarcinoma patients given multimodality therapy. Co-author DOI 10.1002/jso.26650↗
  29. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003442↗
  30. Impact of Intraoperative Dexamethasone on Surgical and Oncologic Outcomes for Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-09013-4↗
  31. Factors Influencing Exercise Following Pancreatic Tumor Resection. Co-author DOI 10.1245/s10434-020-09062-9↗
  32. Measurement of Portal Vein Blood Circulating Tumor Cells is Safe and May Correlate With Outcomes in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-09518-y↗
  33. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2020.2286↗
  34. Permanent endoscopic reversal of Roux-en-Y gastric bypass for diagnosis and long-term palliation of pancreatic cancer. Co-author DOI 10.1016/j.vgie.2020.04.017↗
  35. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000003763↗
  36. The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-08427-4↗

Closest collaborators

The 25 strongest of 104 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Matthew H. G. Katz · 34 shared papers, 2020–2026 · strength 5.63
  2. Ching-Wei David Tzeng · 32 shared papers, 2020–2026 · strength 5.31
  3. Michael P. Kim · 30 shared papers, 2020–2026 · strength 4.77
  4. Jeffrey E. Lee · 25 shared papers, 2020–2026 · strength 3.91
  5. Laura R. Prakash · 22 shared papers, 2020–2026 · strength 3.51
  6. Eugene Jon Koay · 17 shared papers, 2020–2026 · strength 2.37
  7. Robert A. Wolff · 16 shared papers, 2020–2026 · strength 2.26
  8. Rebecca Anne Snyder · 8 shared papers, 2024–2026 · strength 1.87
  9. Shubham Pant · 11 shared papers, 2020–2026 · strength 1.46
  10. Anirban Maitra · 8 shared papers, 2022–2026 · strength 1.23
  11. Jun Okui · 3 shared papers, 2026 · strength 1.17
  12. Michael James Overman · 9 shared papers, 2020–2026 · strength 1.16
  13. Timothy Eric Newhook · 7 shared papers, 2021–2026 · strength 1.14
  14. Dan Zhao · 6 shared papers, 2023–2026 · strength 1.05
  15. Huamin Wang · 7 shared papers, 2021–2024 · strength 0.94
  16. Ethan Bernard Ludmir · 6 shared papers, 2022–2026 · strength 0.89
  17. Brandon George Smaglo · 5 shared papers, 2022–2026 · strength 0.86
  18. Pamela W. Lu · 3 shared papers, 2024–2026 · strength 0.77
  19. Milind M. Javle · 6 shared papers, 2020–2023 · strength 0.67
  20. Hua Wang · 4 shared papers, 2023–2024 · strength 0.63
  21. Deyali Chatterjee · 4 shared papers, 2023–2024 · strength 0.63
  22. Mahmoud Yousef · 3 shared papers, 2025–2026 · strength 0.61
  23. Hop S. Tran Cao · 3 shared papers, 2023–2026 · strength 0.61
  24. Ryan W. Huey · 3 shared papers, 2025–2026 · strength 0.58
  25. Robin D. Wright · 2 shared papers, 2026 · strength 0.56

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.